欧洲-话题@MedSci

#欧洲#

592篇内容 | 6065人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1339123, encodeId=6a981339123ae, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, objectType=article, longId=149623, objectId=297e149623e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=297e149623e6, replyNumber=0, likeNumber=53, createdTime=2018-09-27, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=297e149623e6, moduleTitle=阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=297e149623e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339122, encodeId=b9451339122c6, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, objectType=article, longId=149597, objectId=26f714959eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f714959eaf, replyNumber=0, likeNumber=57, createdTime=2018-09-27, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f714959eaf, moduleTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f714959eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339121, encodeId=79f51339121e7, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局人用药品委员会向欧盟推荐13种药物用于上市, objectType=article, longId=149596, objectId=39d4149596de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d4149596de, replyNumber=0, likeNumber=61, createdTime=2018-09-27, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d4149596de, moduleTitle=欧洲药品管理局人用药品委员会向欧盟推荐13种药物用于上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d4149596de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339120, encodeId=f835133912000, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=BMJ：欧洲学者仅公布一成临床试验结果, objectType=article, longId=149473, objectId=9a881494e305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a881494e305, replyNumber=0, likeNumber=51, createdTime=2018-09-25, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a881494e305, moduleTitle=BMJ：欧洲学者仅公布一成临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a881494e305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339119, encodeId=72a1133911949, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲真实世界研究：噻托溴铵/奥达特罗显著改善COPD患者的身体功能, objectType=article, longId=149160, objectId=5628149160d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5628149160d7, replyNumber=0, likeNumber=17, createdTime=2018-09-21, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5628149160d7, moduleTitle=欧洲真实世界研究：噻托溴铵/奥达特罗显著改善COPD患者的身体功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5628149160d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339118, encodeId=ccb6133911850, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=上海和汉堡将在德合作培养中医研究生，主要针对欧洲西医医生, objectType=article, longId=148821, objectId=ae9d14882166, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae9d14882166, replyNumber=0, likeNumber=68, createdTime=2018-09-15, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae9d14882166, moduleTitle=上海和汉堡将在德合作培养中医研究生，主要针对欧洲西医医生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae9d14882166)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339117, encodeId=9904133911e69, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2018欧洲循证意见书：成人获得性脑损伤物理和康复医学专业实践, objectType=article, longId=148383, objectId=c2b0148383a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b0148383a9, replyNumber=0, likeNumber=16, createdTime=2018-09-08, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b0148383a9, moduleTitle=2018欧洲循证意见书：成人获得性脑损伤物理和康复医学专业实践, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2b0148383a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339116, encodeId=b0631339116e5, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲批准：利伐沙班联合阿司匹林可用于冠心病和外周动脉疾病二级预防, objectType=article, longId=147842, objectId=e4bb14e842ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4bb14e842ec, replyNumber=0, likeNumber=96, createdTime=2018-09-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4bb14e842ec, moduleTitle=欧洲批准：利伐沙班联合阿司匹林可用于冠心病和外周动脉疾病二级预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4bb14e842ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339115, encodeId=bcc5133911540, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2018 欧洲意见书：慢性肾脏疾病磁共振成像生物标志物, objectType=article, longId=147745, objectId=6c7114e745dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c7114e745dc, replyNumber=0, likeNumber=16, createdTime=2018-08-31, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c7114e745dc, moduleTitle=2018 欧洲意见书：慢性肾脏疾病磁共振成像生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c7114e745dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339114, encodeId=64471339114a4, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2018欧洲高血压指南：特殊情况下的高血压, objectType=article, longId=147721, objectId=abb514e721de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abb514e721de, replyNumber=0, likeNumber=58, createdTime=2018-08-31, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abb514e721de, moduleTitle=2018欧洲高血压指南：特殊情况下的高血压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abb514e721de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339113, encodeId=c8a51339113f9, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲血运重建指南：**经桡动脉路径，所有介入都应使用药物支架，新型口服抗凝药地位提升，比伐卢定地位下降, objectType=article, longId=147614, objectId=0d4814e61482, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4814e61482, replyNumber=0, likeNumber=17, createdTime=2018-08-30, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4814e61482, moduleTitle=欧洲血运重建指南：**经桡动脉路径，所有介入都应使用药物支架，新型口服抗凝药地位提升，比伐卢定地位下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4814e61482)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339112, encodeId=4ddf133911204, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2017 欧洲意见书：药物诱导睡眠内镜检查, objectType=article, longId=147510, objectId=b24714e510b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b24714e510b3, replyNumber=0, likeNumber=18, createdTime=2018-08-28, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b24714e510b3, moduleTitle=2017 欧洲意见书：药物诱导睡眠内镜检查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b24714e510b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339111, encodeId=927a1339111d5, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=Eisai/MSD的Lenvima在欧洲被批准用于肝癌的治疗, objectType=article, longId=147384, objectId=744714e38490, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=744714e38490, replyNumber=0, likeNumber=66, createdTime=2018-08-27, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=744714e38490, moduleTitle=Eisai/MSD的Lenvima在欧洲被批准用于肝癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=744714e38490)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339110, encodeId=c605133911023, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2018 欧洲指南：成人血液病患者初级抗真菌预防治疗, objectType=article, longId=146529, objectId=e9b4146529f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9b4146529f5, replyNumber=0, likeNumber=20, createdTime=2018-08-14, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9b4146529f5, moduleTitle=2018 欧洲指南：成人血液病患者初级抗真菌预防治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e9b4146529f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339109, encodeId=7250133910950, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=《2018年欧洲肝病学会丙型肝炎治疗推荐意见》介绍及解读, objectType=article, longId=146294, objectId=348314629422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=348314629422, replyNumber=0, likeNumber=0, createdTime=2018-08-11, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=348314629422, moduleTitle=《2018年欧洲肝病学会丙型肝炎治疗推荐意见》介绍及解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=348314629422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339108, encodeId=bb31133910887, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲药品管理局授予罗氏RG6042为优先药物用于治疗亨廷顿舞蹈症, objectType=article, longId=145827, objectId=80e814582ef0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e814582ef0, replyNumber=0, likeNumber=63, createdTime=2018-08-05, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e814582ef0, moduleTitle=欧洲药品管理局授予罗氏RG6042为优先药物用于治疗亨廷顿舞蹈症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e814582ef0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339107, encodeId=ae2c133910e10, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=诺华CGRPR单抗Erenumab获批成为欧洲偏头痛预防药物, objectType=article, longId=145637, objectId=acc714563eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acc714563eea, replyNumber=0, likeNumber=116, createdTime=2018-08-03, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acc714563eea, moduleTitle=诺华CGRPR单抗Erenumab获批成为欧洲偏头痛预防药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acc714563eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339106, encodeId=58b0133910609, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=2018 欧洲联合共识声明：房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理, objectType=article, longId=145546, objectId=b9f5145546d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9f5145546d0, replyNumber=0, likeNumber=18, createdTime=2018-08-01, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9f5145546d0, moduleTitle=2018 欧洲联合共识声明：房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9f5145546d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339105, encodeId=5b7b133910556, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=CHMP推荐Nucala（mepolizumab）用于治疗重症嗜酸性粒细胞性哮喘的欧洲患儿, objectType=article, longId=145480, objectId=253814548015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=253814548015, replyNumber=0, likeNumber=89, createdTime=2018-07-31, rootId=0, userName=ms9474365431325850, userId=5c442500150, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=253814548015, moduleTitle=CHMP推荐Nucala（mepolizumab）用于治疗重症嗜酸性粒细胞性哮喘的欧洲患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=253814548015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1339104, encodeId=24b4133910410, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, objectTitle=欧洲CHMP维持对Portola制药公司Betrixaban的负面意见, objectType=article, longId=145413, objectId=801d145413f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801d145413f5, replyNumber=0, likeNumber=60, createdTime=2018-07-30, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801d145413f5, moduleTitle=欧洲CHMP维持对Portola制药公司Betrixaban的负面意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801d145413f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

欧洲

2020-05-29

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

阿斯利康的PD-L1单抗Imfinzi欧洲获批用于治疗局部晚期且不可切除的非小细胞肺癌

2018-09-27

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

2018-09-27

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局人用药品委员会向欧盟推荐13种药物用于上市

2018-09-27

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

BMJ：欧洲学者仅公布一成临床试验结果

2018-09-25

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲真实世界研究：噻托溴铵/奥达特罗显著改善COPD患者的身体功能

2018-09-21

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

上海和汉堡将在德合作培养中医研究生，主要针对欧洲西医医生

2018-09-15

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2018欧洲循证意见书：成人获得性脑损伤物理和康复医学专业实践

2018-09-08

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲批准：利伐沙班联合阿司匹林可用于冠心病和外周动脉疾病二级预防

2018-09-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2018 欧洲意见书：慢性肾脏疾病磁共振成像生物标志物

2018-08-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2018欧洲高血压指南：特殊情况下的高血压

2018-08-31

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲血运重建指南：**经桡动脉路径，所有介入都应使用药物支架，新型口服抗凝药地位提升，比伐卢定地位下降

2018-08-30

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2017 欧洲意见书：药物诱导睡眠内镜检查

2018-08-28

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

Eisai/MSD的Lenvima在欧洲被批准用于肝癌的治疗

2018-08-27

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2018 欧洲指南：成人血液病患者初级抗真菌预防治疗

2018-08-14

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

《2018年欧洲肝病学会丙型肝炎治疗推荐意见》介绍及解读

2018-08-11

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

欧洲药品管理局授予罗氏RG6042为优先药物用于治疗亨廷顿舞蹈症

2018-08-05

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

诺华CGRPR单抗Erenumab获批成为欧洲偏头痛预防药物

2018-08-03

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

2018 欧洲联合共识声明：房颤患者表现为急性冠脉综合征和/或经皮心血管介入治疗的抗栓治疗管理

2018-08-01

ms9474365431325850 (审核中...)

前往app查看评论内容

#欧洲#

CHMP推荐Nucala（mepolizumab）用于治疗重症嗜酸性粒细胞性哮喘的欧洲患儿

2018-07-31

智慧医人 (审核中...)

前往app查看评论内容

#欧洲#

欧洲CHMP维持对Portola制药公司Betrixaban的负面意见

2018-07-30

科室
- - 订阅+
  - 更多科室
工具
服务